BFK — Pharmesis International Income Statement
0.000.00%
Last trade - 00:00
- SG$19.65m
- SG$22.52m
- CNY45.64m
- 22
- 19
- 94
- 39
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 37.2 | 47.1 | 52.8 | 50.4 | 45.6 |
Cost of Revenue | |||||
Gross Profit | 19.9 | 23.9 | 25 | 24 | 20.8 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 55.8 | 52.1 | 49.6 | 52.6 | 49.6 |
Operating Profit | -18.6 | -4.94 | 3.15 | -2.23 | -3.98 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.5 | -5.84 | 2.12 | -3.16 | -4.86 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.3 | -5.84 | 1.97 | -3.18 | -4.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -17.7 | -5.83 | 1.17 | -3.56 | -4.96 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -17.7 | -5.83 | 1.17 | -3.56 | -4.96 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.544 | -0.226 | 0.049 | -0.154 | -0.186 |